Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
B. Braun Acquires True Digital Surgery to Strengthen Digital Microsurgery Portfolio
B. Braun SE, a major player in medical technology worldwide, has finalized the full purchase of True Digital Surgery (TDS), a company based in California that specializes in digital robotic-assisted 3D surgical microscopy. This acquisition shows B. Braun’s dedication to pushing forward in digital microsurgery and growing its presence in this rapidly expanding area. B. Braun had already owned a smaller share in TDS, but now, with full ownership, the company’s surgical division Aesculap can use TDS’s knowledge and skills to keep creating new innovations for the Aesculap AEOS platform, which is commonly used in neurosurgery, spinal surgeries, and ENT procedures.
Wellvana ACOs Save Medicare $327 Million in High-Quality Care
Wellvana’s accountable care organizations (ACOs) helped over 800,000 patients nationwide and saved Medicare $327 million during the 2024 performance year, according to the Centers for Medicare and Medicaid Services. These results show Wellvana as the biggest support for hospital-based and rural ACOs in the country. Compared to other value-based care groups, Wellvana achieved 3.0 percent in gross savings, which is better than the 2.1 percent savings from other hospital-led ACO enablers. One of Wellvana’s largest ACOs saved the most among all MSSP ACOs, reaching $169 million in savings.
Precision Bio Shares Phase 1 PBGENE-HBV Trial Data
Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany, on September 12th.
Ant Group’s AI Healthcare App AQ Hits 140 Million Users
At the 2025 INCLUSION · Conference on the Bund in Shanghai, Ant Group’s AI-powered healthcare app AQ has rolled out a new suite of service updates aimed at making healthcare more inclusive and accessible.
Digi International Launches Serial Server: Digi Connect EZ 4 WS For Use in Medical Settings
Digi International, a top company in secure connectivity solutions, has launched its newest serial server that meets the IEC 60601 3rd edition standards, called the Digi Connect EZ 4 WS. This device is made especially for use in medical settings where patient care is the main focus, and it uses Digi’s many years of experience in healthcare technology.
Lōvu Health Raises $8Million Series A to Transform Maternal Care
Lōvu Health, a digital platform that supports mothers and babies from the time of conception through the postpartum period, recently raised $8 million in Series A funding. This funding was led by SJF Ventures, with support from other investors such as Rogue Women’s Fund, Symphonic Capital, and Emmeline Ventures. The company is tackling a major issue in the U.S., where almost half of women skip prenatal or postnatal care because of high costs and limited access. Lōvu provides ongoing and connected maternal care, changing how women receive support before and after childbirth.
Biocon Opens First U.S. Manufacturing Plant in New Jersey
Biocon Limited, a top global biopharmaceutical company listed on BSE and NSE with the ticker BIOCON, has opened its first manufacturing plant in the United States through its wholly owned subsidiary, Biocon Generics Inc. The facility is located in Cranbury, New Jersey. The event to mark its opening was attended by Phil Murphy, the Governor of New Jersey, along with Biocon’s Chairperson Kiran Mazumdar-Shaw, industry experts, partners, and customers.
Lupin Gets FDA Approval For Risperidone Long-Acting Injectable With CGT Exclusivity
Global pharmaceutical company Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone extended-release injectable suspension. The approval covers three different dosage levels: 25 mg, 37.5 mg, and 50 mg per vial, all in single-dose formats. This is the first time Lupin has received approval using the proprietary technology developed by its subsidiary, Nanomi B.V. The product has also been granted 180 days of Competitive Generic Therapy (CGT) exclusivity. Nanomi is a division of Lupin that focuses on researching and developing long-acting injectable medicines, aimed at improving clinical results.
Hoth Submits EMA App for HT-001 Phase II Cancer Trial
Hoth Therapeutics, Inc, a biopharmaceutical company focused on creating new treatments, has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) as part of its plan to expand the Phase II study of HT-001. This experimental topical treatment is meant to help with skin side effects that often happen when patients use Epidermal Growth Factor Receptor inhibitors (EGFRi), which are commonly used in cancer treatments.
To share your insights, please write to us at sudipto@intentamplify.com
